Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 7.5 Contact Hours.
This activity is supported by educational grants from Astellas, Genomic Health, Inc., Medivation, Inc., a Pfizer company, and Sanofi Genzyme.
March 24, 2018
Crowne Plaza® Times Square Manhattan
1605 Broadway (at 49th Street)
New York, NY 10019
Hotel Reservation Website
The congress will focus on key clinical topics in the management of genitourinary (GU) malignancies, including optimal use of chemotherapeutic and local therapies, androgen-deprivation therapies, targeted therapies, radiopharmaceuticals, and immunotherapies. Coverage will include discussions of prognostic/predictive marker application and proactive mitigation of predictable treatment-related adverse effects. Promising new and emerging data in the field will be explored, for example, combining and sequencing treatments across the disease continuum. Key questions concerning the application of landmark clinical trial data (eg, PSA screening, decision making for castrate-sensitive prostate cancer) will be answered during this program. New in 2018, the popular case-based panel discussions will highlight cases submitted by New York GU™ attendees.
Now in its 11th year, the 2018 New York GU™ meeting is not to be missed! The meeting will continue its legacy and tradition of providing clinicians with the valuable knowledge and confidence to maintain state-of-the-art care and optimize outcomes for patients with genitourinary malignancies.
This activity is supported by educational grants from Astellas, Genomic Health, Inc., and Medivation, Inc., a Pfizer company.
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, nuclear medicine physicians, and other healthcare professionals interested in the treatment of GU malignancies may also participate.
After this activity, participants should be better prepared to:
Daniel P. Petrylak, MD
Professor of Medicine, Medical Oncology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Program
Yale Cancer Center
New Haven, CT
Leonard G. Gomella, MD, FACS
The Bernard W. Godwin Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director Jefferson Kimmel Cancer Center Network
Thomas Jefferson University
Jan 30, 2018
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid Malignancies
Jan 30, 2018
Cancer Summaries and Commentaries™: Update from San Diego - Advances in the Treatment of Multiple Myeloma
Jan 31, 2018
Jan 31, 2018